PSDN — AdvisorShares Poseidon Dynamic Cannabis ETF

PSDN Fund Overview

PSDN — AdvisorShares Poseidon Dynamic Cannabis ETF is a US ETF managed by AdvisorShares Trust, categorised as Developed ex-US Real Estate. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.

• Type: US ETF
• Manager: AdvisorShares Trust
• Category: Developed ex-US Real Estate
• Assets under management: $3.02M
• 1-year return: -54.1%
• Ticker: PSDN
• SEC CIK: 0001408970
• SEC series ID: S000074074
• Share class ID: C000231516

PSDN Investment Objective and Strategy

AdvisorShares Poseidon Dynamic Cannabis ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by AdvisorShares Trust.

Investment objective

The AdvisorShares Poseidon Dynamic Cannabis ETF (the Fund) seeks long-term capital appreciation.

Principal investment strategy

The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in (i) securities of companies that derive at least 50% of their net revenue directly from the marijuana and hemp business or from providing services, products or technology to the marijuana and hemp business, and (ii) derivatives that have economic characteristics similar to such securities. The Fund primarily invests in exchange-listed equity securities, including common and preferred stock, of U.S. and foreign mid-, small- and micro-capitalization companies, and in total return swaps intended to provide exposure to such companies. Poseidon Investment Management, LLC (the Sub-Advisor) may seek investment opportunities through initial public offerings (IPOs).

Using total return swaps, the Sub-Advisor may, at its discretion, dynamically adjust the Funds overall market exposure to marijuana and hemp companies through leverage of up to one and a half times (1.5x), or 150% of, the Funds total assets. The Sub-Advisor will adjust the Funds net exposure to leverage in order to seek exposure to a greater rate of growth over the long term and potentially deliver improved risk-adjusted returns, as compared to a fund without leverage. In addition to its investment in securities of companies that derive a significant portion of their revenue from the marijuana and hemp business, and in derivatives providing exposure to such securities, the Fund may invest up to 20% of its assets in securities of companies that, in the opinion of the Sub-Advisor, may have current or future revenues from cannabis-related business or that are registered with the Drug Enforcement Agency (the DEA) specifically for the purpose of handling marijuana for lawful research and development of cannabis or cannabinoid-related products.

Cannabis securities may be categorized among a wide variety of sectors and industries including agriculture, biotechnology, pharmaceuticals, real estate, retail, and finance. The types of companies that may engage in cannabis-related business include companies that conduct medical research, produce drug products, manufacture hemp products, or engage in agricultural activities, real estate activities, or financial services activities. The terms marijuana and cannabis are used interchangeably. Hemp refers to the industrial/commercial use of the cannabis stalk and seed for textiles, foods, papers, body care products, detergents, plastics and building materials. Cannabinoids are the chemical compounds secreted by cannabis plants. Cannabinoids can also be synthetically produced chemical compounds and used in lawful research and development of prescription drugs or other products utilizing cannabinoids as an active ingredient.

The Sub-Advisor believes that continued legislative changes and social acceptance of cannabis in its various formats could lead to significant growth in cannabis-related public corporations. Companies involved in cannabis-related business could also benefit from significant merger and acquisition activity as the cannabis market matures. The Fund will not invest directly in or hold ownership in any companies that engage in cannabis-related business unless permitted by national and local laws of the relevant jurisdiction including, but not limited to, U.S. federal and state laws. The Fund will concentrate at least 25% of its investments in the Pharmaceuticals, Biotechnology & Life Sciences Industry Group within the Health Care Sector. The Fund is non-diversified and may invest a greater percentage of its assets in a particular issuer than a diversified fund.

The Sub-Advisor may use a variety of methods for security selection. As the Fund primarily focuses on certain industries, the Sub-Advisor intends to select companies that it believes have competitive advantages in their respective markets, or those in unique positions for growth and expansion. The Sub-Advisor will utilize fundamental research, market analysis, numerous outside analyst ratings and stock selection rating tools. The Sub-Advisor will carefully consider the Funds amount of equity exposure and leverage when making adjustments at its discretion. In addition, the Sub-Advisor may invest the Funds assets in lesser-known companies that the Sub-Advisor believes have a unique opportunity for growth. At times, the Sub-Advisor may aim to buy certain out-of-favor stocks believed to be at prices below their future potential value, as measured by the Sub-Advisor or outside analysts.

The Fund may sell a security when the Sub-Advisor believes that the security is overvalued or better investment opportunities are available, or to limit position size within the Funds portfolio. In addition, the Fund may lend portfolio securities to brokers, dealers and other financial organizations that meet capital and other credit requirements or certain other criteria. In connection with its securities lending activities, the Fund may invest in repurchase agreements.

PSDN Performance

Total returns for PSDN (as of 2026-10-01), from SEC filings.

PSDN Risk Information

Risk metrics for PSDN, derived from monthly returns in SEC filings.

• 1-year volatility (annualised): 69.3%

PSDN Costs and Fees

PSDN costs about $101 per $10,000 invested per year in fund expenses.

• Net expense ratio: 1.01%
• Gross expense ratio: 2.59%
• Portfolio turnover: 159%
• Brokerage commissions: 24.11 bps of average net assets (SEC N-CEN)

PSDN Cashflows

Over the 12 months to 2023-06, AdvisorShares Poseidon Dynamic Cannabis ETF had net inflows of $1.69M, from monthly SEC N-PORT filings.

PSDN Debt Constituents

No individual debt constituents are reported in AdvisorShares Poseidon Dynamic Cannabis ETF's latest SEC N-PORT filing.

PSDN Prospectus and SEC Filings

Official AdvisorShares Poseidon Dynamic Cannabis ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.

• Prospectus (485BPOS) — filed 2022-10-28
• Prospectus (485BPOS) — filed 2021-11-10
• Portfolio holdings (N-PORT) — filed 2023-08-18
• Portfolio holdings (N-PORT) — filed 2023-05-22
• Portfolio holdings (N-PORT) — filed 2023-02-23
• Annual census (N-CEN) — filed 2023-09-08
• Annual census (N-CEN) — filed 2022-09-08

Related Funds

Other Developed ex-US Real Estate funds tracked on ABC INVEST:

• Vanguard Global Ex-U.s. Real Estate Index Fund (VGRLX)
• Xtrackers International Real Estate ETF (HAUZ)
• Fidelity International Real Estate Fund (FIRAX)
• SPDR® Dow Jones International Real Estate ETF (RWX)
• Third Avenue International Real Estate Value Fund (REIZX)

Data Sources

ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.